India's R&D-based pharma commits to improving health care access

29 July 2012

Improving access through innovation and research and development aimed at finding tomorrow’s cures will continue to remain the primary focus for innovative pharmaceutical companies in India. This was stated at the Organization of Pharmaceutical Producers of India’s (OPPI) Conclave on Access, Innovation and Reach of Healthcare in India held at the Nehru Center in Mumbai last week.

The OPPI says it identifies itself with the country’s national health care objectives and plays an active role in achieving them. Towards this endeavor, the Conclave intended to bring together distinguished globally-acclaimed professionals, experts, government officials and other stakeholders of the health care and allied sectors to chart a way forward to help achieving the health care goals of India.

Price controls on patented drugs planned

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >